US DIAGNOSTIC INC. AND SUBSIDIARIES
--------------------------------------------------------------------------------------------------------------------------------
COMPUTATION OF EARNINGS PER SHARE OF COMMON STOCK
--------------------------------------------------------------------------------------------------------------------------------
EXHIBIT 11
COMPUTATION OF EARNINGS PER SHARE OF COMMON STOCK
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
THREE MONTHS ENDED SEPTEMBER 30, NINE MONTHS ENDED SEPTEMBER 30,
-------------------------------- ---------------------------------
1997 1996 1997 1996
---- ---- ---- ----
PRIMARY EARNINGS PER SHARE:
Weighted average shares outstanding 22,126 18,287 22,124 10,662
Dilutive effect of conversions -- 2,991 -- 3,359
------- -------- ------- --------
Primary weighted average shares of common 22,126 21,278 22,124 14,021
stock and common stock equivalents ======= ======== ======= ========
outstanding
Net income (loss) $(9,848) $1,108 $(19,718) $2,571
Adjustment to net income for interest -- -- -- --
-------- -------- -------- --------
savings, net of related income taxes
Adjusted net income (loss) $(9,848) $1,108 $(19,718) $2,571
======== ======== ======== ========
Earnings (loss) per share - primary $(.45) $.05 $(.89) $.18
===== ==== ===== ====
FULLY DILUTED EARNINGS PER SHARE (1):
Weighted average shares outstanding, 22,600 20,325 22,598 12,254
including escrow shares
Dilutive effect of conversions 1,179 2,957 1,264 4,846
-------- -------- -------- --------
Fully diluted weighted average shares of 23,779 23,282 23,862 17,100
common stock and common stock equivalents ======== ======== ======== ========
outstanding
Net income (loss) $(9,848) $1,108 $(19,718) $2,571
Adjustments to net income for interest -- -- -- --
-------- -------- -------- --------
savings, net of related income taxes
Adjusted net income (loss) $(9,848) $1,108 $(19,718) $2,571
====== ===== ======= =====
Earnings per share - fully diluted $(.41) $.05 $(.83) $.15
===== ==== ===== ====
(l) This calculation is submitted for 1997 in accordance with Regulation SK Item
601(b)(11) although it is contrary to paragraph 40 of APB Opinion No. 15 because
it produces an anti-dilutive result.
